Palisade Bio Ownership
| PALI Stock | USD 2.42 0.02 0.83% |
Shares in Circulation | First Issued 2006-06-30 | Previous Quarter 1.2 M | Current Value 1.5 M | Avarage Shares Outstanding 276.3 K | Quarterly Volatility 932.5 K |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Palisade |
Palisade Stock Ownership Analysis
The company has price-to-book ratio of 0.56. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Palisade Bio recorded a loss per share of 13.26. The entity last dividend was issued on the 18th of July 2019. The firm had 1:15 split on the 8th of April 2024. Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company was founded in 2005 and is headquartered in Carlsbad, California. Palisade Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Palisade Bio contact J Finley at 858 704 4900 or learn more at https://www.palisadebio.com.Besides selling stocks to institutional investors, Palisade Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Palisade Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Palisade Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Palisade Bio Quarterly Liabilities And Stockholders Equity |
|
Palisade Bio Insider Trades History
Only 1.88% of Palisade Bio are currently held by insiders. Unlike Palisade Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Palisade Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Palisade Bio's insider trades
Palisade Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Palisade Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Palisade Bio backward and forwards among themselves. Palisade Bio's institutional investor refers to the entity that pools money to purchase Palisade Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 52 K | Ubs Group Ag | 2024-06-30 | 1.2 K | Tower Research Capital Llc | 2024-06-30 | 738 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 280 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 100.0 | Wells Fargo & Co | 2024-06-30 | 21.0 | Bank Of America Corp | 2024-06-30 | 5.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 |
Palisade Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Palisade Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Palisade Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Palisade Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Palisade Bio Outstanding Bonds
Palisade Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Palisade Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Palisade bonds can be classified according to their maturity, which is the date when Palisade Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Palisade Bio Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.26) | Return On Assets (0.59) | Return On Equity (1.10) |
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.